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Abstract 
Background: Exosomes are nano-sized extracellular vesicles participating in cell-to-cell communication both in 
health and disease. However, the knowledge about the functions and molecular composition of exosomes in the 
upper airways is limited. The aim of the current study was therefore to determine whether nasal exosomes can influ-
ence inflammatory cells and to establish the proteome of nasal lavage fluid-derived exosomes in healthy subjects, 
as well as its alterations in individuals with chronic airway inflammatory diseases [asthma and chronic rhinosinusitis 
(CRS)].
Methods: Nasal lavage fluid was collected from 14 healthy subjects, 15 subjects with asthma and 13 subjects with 
asthma/CRS. Exosomes were isolated with differential centrifugation and the proteome was analysed by LC–MS/MS 
with the application of two exclusion lists as well as using quantitative proteomics. Ingenuity Pathways Analysis and 
GO Term finder was used to predict the functions associated with the exosomal proteome and a migration assay was 
used to analyse the effect on immune cells by nasal exosomes.
Results: Firstly, we demonstrate that nasal exosomes can induce migration of several immune cells, such as mono-
cytes, neutrophils and NK cells in vitro. Secondly, a mass spectrometry approach, with the application of exclusion 
lists, was utilised to generate a comprehensive protein inventory of the exosomes from healthy subjects. The use of 
exclusion lists resulted in the identification of ~15 % additional proteins, and increased the confidence in ~20 % of 
identified proteins. In total, 604 proteins were identified in nasal exosomes and the nasal exosomal proteome showed 
strong associations with immune-related functions, such as immune cell trafficking. Thirdly, a quantitative proteom-
ics approach was used to determine alterations in the exosome proteome as a result of airway inflammatory disease. 
Serum-associated proteins and mucins were more abundant in the exosomes from subjects with respiratory diseases 
compared to healthy controls while proteins with antimicrobial functions and barrier-related proteins had decreased 
expression.
Conclusions: Nasal exosomes were shown to induce the migration of innate immune cells, which may be important 
as the airway epithelium is the first line of defence against pathogens and allergens. The decreased expression in bar-
rier and antimicrobial exosomal proteins in subjects with airway diseases, could possibly contribute to an increased 
susceptibility to infections, which have important clinical implications in disease progression.
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Background
Nano-sized extracellular vesicles, called exosomes, are 
released by all cells, and contain multiple functional mol-
ecules that can be transferred from one cell to another, 
thereby influencing the recipient cell phenotype. The 
presence of exosomes within the lungs has been previ-
ously documented [1], and in 2011 we showed the pres-
ence of exosomes in the nasal cavity [2]. Bronchoalveolar 
lavage fluid (BALF) derived exosomes from asthmatic 
subjects has been shown to influence leukotriene produc-
tion in bronchial epithelial cells [3], as well as displaying 
an altered miRNA profile compared to healthy subjects 
[4], however there is no published information about the 
functionality of exosomes present in the nasal cavity.
Exosomes in the nasal cavity are important to study in 
relation to chronic inflammatory processes, as the excep-
tional filtering capacity of the nose makes it a first line of 
defence against inhaled particles, such as dust, allergens 
and air pollution. Diseases of the airways can alter the 
epithelium and lead to impaired barrier defence func-
tion [5]. Respiratory diseases such as rhinitis, asthma and 
chronic rhinosinusitis (CRS) are common with preva-
lence’s of 27.5, 8.5 and 10.9  % respectively [6–8]. These 
diseases are intricately connected, with the severity of 
asthma being related to the degree of nasal symptoms [9]. 
However, it is not known whether exosomes in the nose 
are altered during chronic airway inflammatory diseases 
such as CRS and asthma, which is of particular interest as 
this is the site of inflammation.
We hypothesize that exosomes in the nasal cav-
ity have biological functions, and that their molecular 
components are changed among individuals with dif-
ferent respiratory diseases. The aim of the current study 
was therefore to determine whether nasal exosomes can 
induce an inflammatory cell migratory phenotype, and 
to relate any such function with the nasal exosomal pro-
teome. Additionally, we aimed to determine whether 
the nasal exosomal proteome is altered in patients with 
signs of chronic rhinosinusitis and asthma. The base-
line nasal exosomal proteome in healthy individuals was 
determined utilising a dynamic exclusion LC–MS/MS 
approach, while the nasal exosomal proteome in subjects 
with asthma and CRS was compared to controls using a 
quantitative proteomics approach with tandem mass tags 
(TMT®).
Methods
Study subjects
Two separate studies were conducted, study I and II. 
Study I was performed to determine the baseline protein 
cargo of nasal exosomes in healthy subjects and study II 
was performed to determine the alteration in the exo-
somal proteome during chronic airway inflammation by 
quantitative proteomics. Study I participants were five 
healthy non-smoking female subjects, with no current 
asthma or nasal symptoms. Four subjects were used to 
create two pools, pool A and pool B, with two subjects 
per pool (Fig. 1, study I). Samples from the fifth subject 
were used for validation experiments. In addition to the 
samples used for the baseline proteome, additional sam-
ples were obtained from the four subjects in the two 
pools for validation experiments.
Study II participants were selected from question-
naire respondents in the West Sweden Asthma Study [6], 
that had undergone a clinical examination at the Kreft-
ing Research Centre in Gothenburg. The clinical exami-
nation included skin prick tests, fraction of exhaled 
nitric oxide (FeNO), spirometry and a methacholine 
challenge. Study participants attending the clinical 
examination and fulfilling inclusion criteria described 
below, were invited to participate in a study on asthma 
and chronic rhinosinusitis (CRS) where several clini-
cal samples were collected, including nasal lavage fluid 
(NLF). Several groups of subjects were analysed in this 
study; healthy controls (controls) (n =  9), subjects with 
asthma (asthma only) (n =  13), and subjects with both 
asthma and CRS (asthma + CRS) (n = 15). As the con-
trol group of nine subjects was too small to divide into 
two pools, the five healthy subjects in study I under-
went the clinical examination and was also included as 
controls in study II, giving 14 subjects in the control 
group. Two pools per group was created; control pool 
A (n =  7), control pool B (n =  7), asthma only pool A 
(n = 7), asthma only pool B (n = 6), asthma + CRS Pool 
A (n = 7) and asthma + CRS Pool B (n = 8) (Fig. 1, study 
II). Subjects with CRS were defined as those meeting the 
nasal symptoms outlined in the EPOS2012 definition of 
CRS [10]. That is, subjects with two or more symptoms 
for  ≥12  weeks, with one symptom being nasal block-
age/obstruction or rhinorrhoea. Other symptoms could 
be facial pain or reduction/loss of smell. Subjects with 
asthma were defined as those with physician-diagnosed 
asthma, with at least one current symptom of; wheeze, 
trouble breathing, or sudden breathlessness or use of 
asthma medication. Those grouped into asthma only, 
did not meet the EPOS2012 criteria for CRS. Subjects 
in the asthma + CRS group fulfilled both the criteria for 
asthma and CRS.
All subject included had withdrawn from antihista-
mines for 72 h, long acting beta agonist (LABA) for 24 h 
and short acting beta agonist (SABA) for 8 h and Spiriva 
for 24 h prior to sample collection.
Both study I and study II were approved by the Regional 
Ethical Approval Committee in Gothenburg, Sweden 
(no. 593-08) with written informed consent given by all 
participants.
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Collection of nasal lavage and isolation of exosomes
NLF was collected as previously described [2]. Briefly, 5 ml 
of saline was instilled in the left nostril of the subjects, while 
tilting their head back. NLF was collected by passive drip-
ping of the fluid into a container when subjects tilted their 
head forward. This procedure was repeated for the right 
nostril, before the samples were centrifuged for 10 min at 
300×g at 4 °C to pellet the cells. The supernatant was trans-
ferred to new tubes and stored at −80 °C. For study I, NLF 
was collected at multiple occasions from each participant, 
while for study II, NLF was collected only once per par-
ticipant. Pool A and B for the LC–MS/MS experiment in 
study I consisted of 70  ml NLF each, while the pools for 
study II consisted of 20–30 ml NLF each. Exosome isola-
tion was performed as previously described [2]. Briefly, 
NLF was thawed and transferred to ultracentrifuge tubes, 
with the remaining tube volume filled with PBS, before 
centrifuged at 16,500×g for 20 min at 4 °C to remove cells, 
cell debris and larger extracellular vesicles. The supernatant 
was filtered through a 0.2 µm filter (Starstedt, Nümbrecht-
Rommelsdorf, Germany) before exosomes were pelleted by 
ultracentrifugation at 120,000×g for 70 min at 4 °C (Ti70 or 
Ti45 fixed angle rotors in a Optima L-90K Ultracentrifuge, 
Beckman Coulter, Bromma, Sweden).
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Pool A
n = 2
Healthy 
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Fig. 1 Schematic overview of the experimental workflow for the mass spectrometry part of study I and II. In study I, the protein content of 
exosomes from healthy individuals was analysed. Protein extracted from the isolated exosomes was subjected to strong cation exchange chroma-
tography fractionation before analysis with a nano LC–MS/MS instrument. After the first acquisition all identified peptides were used to construct 
an exclusion list that was applied during the second acquisition. This was repeated for the third acquisition. Study II aimed to explore quantitative 
differences in the protein content of exosomes from respiratory diseases. The digested peptides were labelled with TMT reagents and subjected to 
fractionation before being analysed by nano LC–MS/MS. The resulting spectra from both study I and study II were searched in a database for identi-
ties and the reporter ions from the TMT reagents were used to quantify proteins in study II. All datasets were analysed with Ingenuity Pathways 
Analysis and GO Term Finder to identify enriched and associated cellular components, biological functions and processes
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Immune cell isolation and migration assay
Human monocytes, natural killer cells (NK cells) and 
neutrophils were isolated from blood collected from 
healthy donors in EDTA tubes. For NK cells and mono-
cytes peripheral mononuclear cells were first isolated 
using Leucosep® Tubes (Greiner Bio-One GmbH, Fric-
kenhausen, Germany) and ficoll according to the manu-
facturer’s protocol. Monocytes and NK cells were then 
isolated from the peripheral mononuclear cells using 
the Monocyte Isolation Kit II and NK Cell Isolation Kit 
(Miltenyi GmbH, Bergisch Glagbach, Germany) accord-
ing to the manufacturer’s protocol. The purity of the iso-
lated monocytes were determined by the detection of 
CD14 (BD Bioscience) by a FACSAria. The purity of the 
isolated NK cells were determined by a FACSAria and 
the detection of CD56 and CD16 and the absence of CD3 
(BD Bioscience). Neutrophils were isolated directly from 
blood using the MACSxpress® Neutrophil Isolation Kit 
(Miltenyi GmbH)) and purity was determined by May 
Grünwald—Gimsa stain and morphological inspection 
using a microscope. All cells were seeded in IMDM or 
RPMI-1640 supplemented with 100 units/ml penicillin, 
100 µg/ml streptomycin and 110 µg/ml sodium pyruvate 
(Sigma-Aldrich).
The isolated monocytes (35,000 cells per well) were 
seeded to adhere onto the membrane of the lower cham-
ber of a Boyden chemotaxis chamber (Neuro Probe Inc., 
Gaithersburg, MD, USA) in inverted orientation for 4 h. 
The assembly was inverted back to normal orientation 
prior to the start of the assay. NK cells (250,000 cells per 
well) and neutrophils (170,000 cells per well) were seeded 
in the upper chamber of a Boyden chemotaxis chamber. 
Thirty microliters of different dosages of NLF-derived 
exosomes (0.3–100 µg/ml) in supplemented media were 
added to the upper chamber for monocytes and to the 
lower chamber for NK cells and neutrophils. A 0.1 % gel-
atin coated 8 μm (monocytes and neutrophils) or a 5 µm 
(NK cells) pore size membrane filter was placed between 
the upper and the lower chamber (Neuro Probe, Gaith-
ersburg, MD). The cells were then incubated for 12  h 
(monocytes and NK cells) or 5 h (neutrophils) in a 37 °C 
humidified incubator with 5 % CO2. For monocytes, the 
cells that had migrated towards the upper chamber mem-
brane filter side were analysed. These cells were fixed in 
methanol for 10 min, stained with Giemsa and examined 
with a microscope (Zeiss Axioplan 2, Carl Zeiss, Jena, 
Germany). Data for each treatment are shown as cells 
per field of view and compared with untreated wells. For 
NK cells and neutrophils analysis of migrated cells was 
performed on the cells that had migrated into the lower 
chamber media. These cells were counted with a Bürker 
chamber and Trypan blue. Data for each treatment are 
shown as cells per µl and compared with untreated wells.
Protein extraction and digestion
Proteins were extracted using lysis buffer [8 M urea, 4 % 
CHAPS, 0.2  % SDS, 1  mM EDTA, 50  mM triethylam-
monium bicarbonate (TEAB, pH 8.5)] and sonication in 
a water bath. Study I exosomes were extracted in 100 µl 
lysis buffer and sonicated for 3  ×  20  s with 20  s rest 
between bursts, while study II exosomes were extracted in 
50 µl lysis buffer and sonicated 3 × 5 min with 1 min rest 
between bursts. The samples were vortexed briefly and 
centrifuged before the protein concentration of each sam-
ple was determined using the Pierce 660 nm Protein Assay 
Reagent (Thermo Fisher Scientific Inc., Waltham, MA, 
USA). Study I pool A protein (87 µg), study I pool B pro-
tein (68 µg) and study II pools (35 µg each) were diluted 
fourfold to give a final concentration of 250  mM TEAB 
(pH 8.5), 2 M urea, 1 % CHAPS, 0.05 % SDS and 0.25 mM 
EDTA. A reference pool sample for study II was made by 
pooling aliquots of the samples with equal amounts of 
each health/disease represented. The refrence pool was 
treated and diluted identically  to the samples. The sam-
ples were reduced with 2  µl 50  mM tris(2-carboxyethyl)
phosphine) (TCEP) and incubated for 60  min at 37  °C) 
(study I) or incubated, shaking, at room temperature for 
40 min before incubated at 37 °C for 40 min (study II). The 
samples were then alkylated in 1 µl 200 mM methyl meth-
anethiolsulfonate (MMTS) with 20  min incubation at 
room temperature. Digestion of the proteins was achieved 
by adding 50 µl milli-Q water to 20 µg trypsin (Promega 
Corporation, WI, USA), with 10 µl trypsin added to each 
sample and incubated overnight at 37 °C.
Tandem mass tags labelling of peptides (study II)
Digested peptides from each sample in study II were 
labelled with reagents from the TMTsixplex Label Rea-
gent Set (Pierce through Thermo Fisher Scientific) 
according to manufacturer’s instructions. Each sample 
in the set, consisting of one pooled reference sample and 
the pooled subject samples, was labelled with the TMT 
reagents. The reference pool, control, asthma + CRS and 
asthma only samples were labelled with reagents TMT6-
126, TMT6-127, TMT6-128 and TMT6-129 respectively.
Strong cation exchange fractionation of peptides
Strong cation exchange (SCX) chromatography was used 
to remove unbound TMT reagents (study II) and reduce 
the sample complexity by fractionation (study I and II). 
The concentrated peptides were acidified with 10 % for-
mic acid (FA) and diluted with SCX solvent A [25  mM 
ammonium formate, pH 2.8, 25  % acetonitrile (ACN)] 
and injected onto a PolySULFOETHYL A SCX column 
(2.1  mm i.d. ×  10  cm length, 5  μm particle size, 300 Å 
pore size). SCX chromatography and fractionation was 
carried out on an ÄKTA purifier system (GE Healthcare, 
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Waukesha, WI, USA) at 0.25  mL/min flow rate using 
the following gradient: 0 % B (500 mM ammonium for-
mate, pH 2.8, 25 % ACN) for 5 min; 0–40 % B for 20 min; 
40–100 % B for 10 min and 100 % B held for 10 min. UV 
absorbance at 254 and 280 nm was monitored while frac-
tions were collected at 0.5 mL intervals and the volume 
reduced in a SpeedVac. The peptide containing fractions 
were combined with their adjacent fractions (two or three 
together) resulting in eight and nine fractions for study 
I pool A and B respectively and 10 fractions in study II 
samples. Combined SCX fractions were desalted on Pep-
Clean C18 spin columns according to manufacturer’s 
instructions (Thermo Fisher Scientific, Inc., Waltham, 
MA, USA).
NanoLC‑MS/MS analysis on LTQ‑Orbitrap Velos instrument
Study I: The desalted and dried fractions were recon-
stituted into 0.1  % FA and analysed on a LTQ-Orbitrap 
Velos (Thermo Fisher Scientific) interfaced with an in-
house constructed nano-LC column [11]. Two micro-
liter sample injections were made with an Easy-nLC 
autosampler (Thermo Fisher Scientific), running at 
200 nL/min. The peptides were trapped on a pre-column 
(45 × 0.075 mm i.d.) and separated on a reversed phase 
column, 200  ×  0.075  mm, packed with 3  μm Reprosil-
Pur C18-AQ particles. The gradient was as followed; 
0–60 min 7–37 % ACN, 0.2 % FA, up to 80 % ACN, 0.2 % 
FA over 7 min and the last 3 min at 80 % ACN, 0.1 % FA.
LTQ-Orbitrap Velos settings were: spray voltage 1.6 kV, 
1 microscan for MS1 scans at 60000 resolution (m/z 400), 
full MS mass range m/z 400–1800. The LTQ-Orbitrap 
Velos was operated in a data-dependent mode, with one 
MS1 FTMS precursor ion scan followed by collision 
induced dissociation (CID) MS2 scans of the ten most 
abundant doubly or multiply protonated ions in each 
FTMS scan. MS2 were collected with 1 microscans and 
a collision energy of 35  %. Dynamic exclusion within 
20 ppm for 30 s was used after two repeats of MS2 of a 
precursor ion.
Exclusion lists were applied to more thoroughly inves-
tigate the proteome of healthy exosomes. Exclusion lists 
were prepared using the data base search results and 
compiling a list of m/z for all spectra matches that passed 
the criteria for identification within a 3  min retention 
window and five decimals precision. A second 2 µl injec-
tion of each sample was analysed with the application of 
an exclusion list, with the peptides identified in the first 
acquisition of each fraction being excluded from the MS2 
analysis. A third sample was also analysed with peptides 
identified in the second acquisition per fraction excluded 
from MS2 analysis.
Study II: The analysis parameters and instrument set-
tings for study II were as above for study I, with the 
following modifications: The gradient was as follows: 
0–60 min 5–25 % ACN, 60–70 min 25–40 % ACN, up to 
80 % ACN over 10 min and held at 80 % ACN for 10 min. 
The LTQ-Orbitrap Velos was operated in a data-depend-
ent mode with the top ten precursors from each MS1 
scan selected for MS2 with high energy collision dissocia-
tion (HCD). The MS2 settings were as follows: collision 
energy of 40 %.
Database search for protein identification (study I) 
and TMT quantitation (study II)
Study I: All MS raw data files per sample were merged 
for protein identification using Proteome Discoverer ver-
sion 1.3 (Thermo Fisher Scientific). The database search 
was performed by Mascot search engine using the fol-
lowing criteria: Homo sapiens in SwissProt protein data-
base (January 2012 FASTA db: SwissProt_2011_11.fasta. 
Version: 2.3 The number of human protein sequences 
were 20252 in the Swissprot database version Novem-
ber 2011.), MS peptide tolerance as 5 ppm, MS/MS tol-
erance as 0.5  Da, trypsin digestion allowing one missed 
cleavages with variable modifications; methionine oxida-
tion and cysteine methylthiolation. The detected protein 
threshold was set to a false discovery rate (FDR) of 1 % 
confidence on peptide level (which resulted in a mascot 
significance threshold of 0.009) and identified proteins 
were grouped by sharing the same sequences to minimise 
redundancy. A final database search was performed to 
establish a nasal exosome proteome, using the same cri-
teria as above, on a combination list of all three runs from 
both pools.
Study II: The MS raw data files from all fractions for 
one set were merged for relative quantification and iden-
tification using Proteome Discoverer 1.3 (Thermo Fisher 
Scientific). The database search was performed as above 
for study I with additional fixed modifications of lysine 
TMT6plex and N-terminal TMT6plex. For TMT quan-
tification, the ratios of the TMT reporter ion intensities 
in the MS/MS spectra (126.12–130.14) from raw datasets 
were used to calculate fold changes between samples. 
Ratios were derived from Proteome Discoverer version 
1.3 using the following criteria: 80 ppm mass tolerance of 
the reporter ions and calculating the intensity for the cen-
troid peak, TMT reagent purity correction factors were 
used stated in the product data sheet thus recalculating 
the ratio depending on the reporter purity and adjacent 
reporters, the minimum ion intensity of a reporter was 
set to a threshold of 200 and missing values for reporter 
ions were replaced with the minimum intensity of the 
noise level in the spectra. Only unique peptides for a pro-
tein were considered for relative quantitation. Proteome 
Discoverer normalized the channel ratios, for each chan-
nel, normalized all peptide ratios by the median peptide 
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ratio. The median protein ratio should be 1. The nor-
malized ratios were exported into Excel for manual data 
interpretation. The detected protein threshold was set to 
a FDR of 1 % confidence on peptide level (which resulted 
in a mascot significance threshold of 0.0241).
Bioinformatics analysis of proteomic data
Identified and quantified proteins were further analysed 
using Ingenuity Pathways Analysis (IPA) (Ingenuity® 
Systems, http://www.ingenuity.com) to determine the 
most strongly associated functions and pathways. The 
dataset, containing gene accession numbers and corre-
sponding expression values, was uploaded to IPA [(ver-
sion 11904312, 12402621 (study I) and 14400082 (study 
II)]. Each identifier, where possible, was mapped to the 
corresponding object in the Ingenuity Pathways Analy-
sis Knowledge Base (IPAKB). The fold changes for study 
II were calculated by dividing the two disease samples 
(Asthma only and Asthma + CRS) of pool A by the con-
trol of pool A and the disease samples of pool B by the 
control of pool B for comparisons of interest. Further-
more, the disease samples were compared to each other 
within each pool to find disease specific differences. 
The functional analysis of the dataset identified the bio-
logical functions and/or diseases most significant to the 
dataset. Molecules from the study II dataset that met the 
fold change cut-off of 1.3 were considered for analysis. 
A right‐tailed Fisher’s exact test was used to calculate a 
P value, determining the probability that each biological 
function and/or disease assigned to that dataset is due 
to chance alone. A Benjamini-Hochberg multiple testing 
correction was also applied.
The Gene Ontology (GO) is an initiative to describe 
biological functions, molecular processes and cellu-
lar components of genes. An open source software, GO 
Term Finder (http://www.go.princeton.edu/cgi-bin/
GOTermFinder) [12], was used to analyse the enriched 
GO terms of the nasal exosome proteome and draw con-
clusions about the statistical significance of each gene 
ontology term compared to the genomic frequency. 
The annotation of GOA  +  Ensembl Xrefs—H. Sapiens 
(human) was used to determine the enriched terms. An 
interactive Venn diagram tool, VENNY (http://www.bio-
infogp.cnb.csic.es/tools/venny/index.html), was used for 
comparing lists of proteins [13]. Information from the 
exosome database EVpedia (http://www.evpedia.info/) 
[14] were accessed July 2015.
Nine published exosomal proteome were used for 
analyses and included particularly relevant proteomes of 
healthy body fluid exosomes similar to nasal exosomes, 
i.e. from a mixed cellular origin, such as breast milk [15], 
semen [16], plasma [17], parotid saliva [18], saliva [19] 
and two sets from urine (Urine 1 http://www.dir.nhlbi.
nih.gov/papers/lkem/exosome/) [20, 21] and Urine 2 
[22]), as well as exosomes from two primary cell cultures 
(trabecular meshwork cells from the eye [23] and trache-
obronchial ciliated epithelial cells [24]).
Protein measurement for validation experiments
Exosomes were isolated as described above and resus-
pended in PBS. The protein concentration was deter-
mined by Pierce® BCA Protein Assay Kit according to the 
manufacturer’s instructions (Thermo Fisher Scientific).
Validation of mass spectrometry‑identified proteins 
by flow cytometry
Exosomes (20  µg/40,000 beads) were incubated with 
anti-MHC class II-coated beads (custom-made by Dynal, 
Oslo, Norway, and kindly provided by S. Gabrielsson, 
Karolinska Institute, Stockholm, Sweden) or anti-CD63-
coated beads (Life Technologies, Carlsbad, CA, USA) 
overnight at 4  °C with gentle agitation. The exosome-
bead complexes were processed as described earlier [2, 
25]. Briefly, the exosome-bead complexes were incubated 
with human IgG for 15 min at 4 °C, washed twice, before 
incubated with anti-CD9 (clone M-L13), anti-CD14 
(clone MφP9), anti-CD63 (clone H5C6) antibodies or 
the appropriate isotype control for 40 min (all antibodies 
were from BD Bioscience, San Jose, CA, USA). The exo-
some-bead complexes were washed twice before analysed 
with FACSAria (BD Bioscience) and FlowJo software (Tri 
Star Inc, Ashland, OR, USA).
Validation of mass spectrometry‑identified proteins 
by Western Blot
Exosomes were isolated as described above and dissolved 
in 20  mM TrisHCl with 1  % SDS. As a control, mono-
cyte-derived macrophages from buffy coat were used. 
To lyse the exosomes and the cells, the samples were 
freeze/thawed once at −20  °C and then sonicated twice 
for 5  min with vortexing between bursts. The samples 
were centrifuged at 13,000×g for 5 min and the superna-
tant were used for further analysis. Proteins (20 µg/well) 
were loaded and separated on NuPAGE® Novex 4−12 % 
Bis–Tris gels (Invitrogen through Life Technologies) and 
transferred onto nitrocellulose membranes (Invitrogen 
through Life Technologies) according to the manufac-
turer’s instructions, except for the transfer buffer, which 
was modified to 5  % methanol and 0.01  % SDS. The 
membranes were blocked overnight with 0.5  % Blotting 
Grade Blocker Non-Fat Dry Milk (Bio-Rad Laboratories, 
Hercules, CS, USA) in TBS, before being washed three 
times. For all washes, TBS-Tween (TBST) was used. The 
membranes were then incubated with either mouse-anti-
human iNOS (1:1000; clone 2D2-B2; R&D Systems, Min-
neapolis, MN, USA), mouse-anti-human S100A8 (1:250; 
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clone #749916; R&D Systems), mouse-anti-human 
TSG101 (1:1000; clone 4A10; Abcam, Cambridge, U.K.) 
or rabbit-anti-human calnexin (1:1000; clone H-70; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) diluted in 
0.25 % non-fat dry milk in TBST for 2 h. The membranes 
were washed three times before incubation with the sec-
ondary antibody for 1 h. Secondary antibodies used were; 
donkey-anti-rabbit (1:10,000, Amersham through GE 
Healthcare) and sheep-anti-mouse (1:2000, Amersham 
through GE Healthcare), diluted in 0.25  % non-fat dry 
milk in TBST. The membranes were then analysed with 
the Amersham ECL Plus Western Blotting Detection Sys-
tem (GE Healthcare) and a VersaDoc 4000 MP (Bio-Rad 
Laboratories).
NOS activity assay
The enzymatic activity of nitric oxide synthase (NOS) was 
measured with the Ultra Sensitive Assay for Nitric Oxide 
Synthase (Oxford Biomedical Research, Rochester Hills, 
MI, USA), according to manufacturer’s instructions. 
Shortly, the exosomes were lysed (sonication 2 × 3 min) 
before incubated with reaction buffer, NADPH part A, 
NADPH part B and NOS cofactors for 6 h at 37  °C and 
placed on ice for 5 min. The control samples were kept at 
−20  °C until this point. Nitrate reductase was added to 
both samples and control samples and incubated at room 
temperature for 20 min. The samples were centrifuged at 
12,500 rpm, for 5 min at 4  °C and the supernatant were 
transferred to a 96 well plate in duplicates. Colour rea-
gent 1 and 2 was added and the samples were vortexed 
for 5 min before being analysed at 540 nm.
Statistical analysis
Clinical measurements were analysed using the Mann–
Whitney U test and cell migration were analysed using 
Kruskal–Wallis test followed by Dunn’s multiple compar-
isons test in GraphPad Prism 6 (GraphPad Software Inc., 
La Jolla, CA, USA) to determine significant differences.
Results and discussion
Nasal lavage‑derived exosomes induce cell migration 
in primary immune cells
We have previously reported on the presence of 
exosomes in the upper airways by analysing nasal lavage 
fluid (NLF) [2]. However, the possible biological func-
tions of these nasal-derived exosomes have yet to be 
determined. Therefore, exosomes were isolated from NLF 
of healthy subjects, who showed no signs of decreased 
lung function or active inflammation, as determined by 
forced expiratory volume in 1  s (FEV1) and fractional 
exhaled nitric oxide (FeNO) respectively (Table 1, study 
I). To determine whether nasal exosomes can participate 
in innate immunity and induce immune cell trafficking, 
a cell migration assay was performed. Monocytes, NK 
cells and neutrophils isolated from blood were added to 
one of the chambers of a Boyden chemotaxis chamber, 
and different doses of nasal exosomes were added to the 
other chamber, with the number of cells migrating into 
the exosome-containing chamber determined after 5 or 
12 h of incubation. Figure 2a shows that nasal exosomes 
induce a significant and dose-dependent migration of 
primary monocytes, NK cells and neutrophils. This sug-
gests that nasal exosomes have the ability to participate 
in cell communication of the immune cells in the upper 
airways, complementing what has previously been shown 
for BALF exosomes in the lower airways [3, 26].
Identification of nasal exosomal proteins by exclusion 
list‑based LC–MS/MS
To determine whether the migration-inducing effects 
of nasal exosomes are related to their protein cargo, a 
detailed mass spectrometry approach was utilised. Exo-
somal protein was isolated from two pools of NLF and 
each sample was analysed using exclusion list based LC–
MS/MS in order to thoroughly interrogate the proteome 
[27, 28]. After each acquisition, exclusion lists were con-
structed to exclude the peptides previously identified 
from the subsequent LC–MS/MS analysis, with each 
sample being analysed three times in total using two 
exclusion lists.
Analysis of the exosomal proteins from pool A iden-
tified 382 proteins in the first acquisition, with the 
second and third acquisitions identifying 30 and 11 
additional proteins respectively. Analysis of the exoso-
mal protein from pool B identified 451 proteins in the 
first acquisition, while the second and third acquisitions 
identified 50 and 39 new proteins respectively. In total, 
the two exclusion lists applied for pool A and B identi-
fied 11 and 20  % new proteins respectively compared 
to the first LC–MS/MS acquisition alone, showing that 
additional proteins can be found by the exclusion list 
approach (Fig. 2b). Important exosomal proteins such as 
annexin A1, rab-14, 14-3-3 protein epsilon, LAMP and 
heat shock protein HSP 90-alpha, were among the new 
proteins identified in the second and third acquisitions, 
demonstrating that exclusion lists can assist in a more 
thorough analysis of the exosomal proteome. Further-
more, the application of exclusion lists also increased the 
coverage of several proteins, by increasing the number 
of unique peptides identified for proteins found in the 
first acquisition. In total, 173 proteins in pool A and B 
gained one or more unique peptides by using exclusion 
lists (Fig. 2c). This increased coverage is especially valua-
ble for the proteins identified with a single peptide in the 
first acquisition which can be confirmed by additional 
unique peptides in the additional acquisitions. Thus, 
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Table 1 Clinical characteristics of subjects participating in study I and II
Where appropriate, data are expressed as mean ± SEM
All subject included had withdrawn from antihistamines for 72 h, long acting beta agonist (LABA) for 24 h and short acting beta agonist (SABA) for 8 h and Spiriva for 
24 h prior to sample collection
M male; F female; FEV1 forced expiratory volume in 1 s; FeNO fractional exhaled nitric oxide; SPT skin prick test
a The subjects in study I are also included in study II as controls
b One value missing
Study I Study II
Healthy  
(n = 5)
Controla  
(n = 14)
Asthma + CRS  
(n = 15)
Asthma only 
(n = 13)
Sex (M/F) 0/5 5/9 4/11 3/10
Age (years) 41 ± 7 40 ± 3 38 ± 3 44 ± 3
Body mass index 25.2 ± 1.2 24.4 ± 0.5 25.5 ± 0.9 27.4 ± 1.4
FEV1 (% predicted) 111 ± 6 101 ± 4 96 ± 4 93 ± 4
FeNO (ppb) 12 ± 1 15 ± 2 15 ± 5 19 ± 3
SPT (neg/pos) 3/1b 10/3b 4/11 2/11
# of peptides identi-
acquisition 1
Pool A Pool B
Proteins that gained 1 or more unique peptides 
in acquisition 2 and 3 (%)
1 6.2 13.8
2 15.9 20.3
3 29.0 25.0
4 28.6 56.5
5 or more 51.2 66.7
Total 15.4 25.3
11
4
99
15
2663205
Acquision 1
Acquision 3
Acquision  2
Pool A
39
12
163
40
3883165
Acquision 1
Acquision 3
Acquision 2
Pool B
a
b
c
Fig. 2 Nasal exosomes induce immune cell migration and the use of exclusion lists during mass spectrometry identifies new proteins and pep-
tides. a Human monocytes, NK cells and neutrophils isolated from blood were added to one of the chambers of a Boyden chamber (35,000–250,000 
cells/well). To the other chamber 30 µl of the different doses of nasal exosomes were added. Media was used as a control. After five (neutrophils) 
or 12 (monocytes and NK cells) hours the number of cells migrated to the exosome-containing chamber on the other side of the membrane were 
analysed. Kruskal–Wallis test followed by Dunn’s multiple comparisons test were used to determine significant differences where all concentrations 
were only compared to the control. P values * <0.05, ** <0.01, *** <0.001, **** <0.0001. b The Venn diagrams compare the proteins identified in the 
first acquisition (black font), the second acquisition (red font) and the third acquisition (blue font) and shows that the utilisation of exclusion lists in 
re-acquisitions led to increased numbers of identified proteins. c The utilisation of exclusion lists also resulted in the identification of new unique 
peptides for proteins previously identified, which increased the coverage and confidence for these proteins. Proteins were divided into groups 
based on the number of peptides identified in the first acquisition for each protein (1–5 or more). Data are presented as the percentage of proteins 
identified with additional unique peptides in the second or third acquisition in each category
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the application of exclusion lists to proteomic analyses 
of exosomes can result in a more detailed description of 
proteomes, which is important for the understanding of 
exosomal biogenesis and uptake mechanisms and ulti-
mately, for predicting exosomal protein-associated func-
tions in health and various disorders.
The spectra from all acquisitions, from both pools, 
were combined to perform a new database search. This 
search identified 604 proteins which were used for down-
stream analyses (Additional file 1: Table S1). Of the 604 
proteins, 289 were identified with two or more peptides 
and 293 were identified in both pools (Additional file 1: 
Table S1, “Identified in both pools”). To confirm the pres-
ence of exosomes in the nasal lavage isolates, the iden-
tified proteome was compared with a proposed “core 
exosome proteome” of 143 proteins [29], of which 82 
(57  %) were identified in the nasal exosomal proteome 
(Additional file  1: Table S1, “Core exosome proteome”). 
The proteomic detection of previously identified exoso-
mal proteins supports the validity of the exosome isola-
tion method, as well as the sensitivity of the proteomic 
approach applied in the present study.
The nasal exosome proteome is specifically associated 
with immune‑related functions
The 604 proteins of the nasal exosome proteome were 
analysed using GO Term Finder to identify the most 
enriched GO terms and the associated proteins. The cel-
lular components most enriched in nasal exosomes were 
related to parts of the extracellular region, the plasma 
membrane and the cytoplasmic region (Fig. 3a), but nasal 
exosomes also contained 94 proteins associated with the 
GO term membrane-bound vesicles (Additional file  1: 
Table S1, “Membrane-bound vesicle proteins”), which 
has exosomes as a subgroup.
Importantly, biological processes enriched in the 
nasal exosomal proteome included defense  response and 
immune system processes (Fig.  3b) and more specifi-
cally, 80 proteins categorised as innate immune response, 
including S100 proteins, inducible nitric oxide synthase 
(NOS2) and BPIF proteins, supporting an immune-
related function for nasal exosomes.
Ingenuity pathway analysis (IPA) was utilised to fur-
ther analyse the possible functions associated with the 
nasal exosome proteome, revealing associations with 
biological functions such as cellular movement, der-
matological diseases and conditions and cancer, as well 
as immune cell trafficking and inflammatory response 
(Fig. 3c), again connecting the nasal exosomal proteome 
to immune-related functions. To determine the speci-
ficity of the identified associated functions, the datasets 
of nine published exosome proteome from relevant, 
healthy, human in vivo sources were also analysed using 
IPA and compared to the nasal exosomal IPA analysis. 
The comparison of these studies to the nasal exosome 
proteome showed that the biological functions of cel-
lular movement, dermatological diseases and conditions 
and cancer are common to multiple studies and are 
often the top functions (Fig.  3d). By contrast, immune 
cell trafficking, inflammatory response and hematologi-
cal system development and function were only the top 
functions in one of the nine studies analysed. Of the 604 
proteins in the nasal exosome, 205 proteins belonged to 
one or more of these specifically associated functions 
(Additional file 1: Table S1, “Immune-related proteins”). 
Specific annotations for immune cell trafficking and 
inflammatory response included migration, movement 
and adhesion of various immune cells, including leuko-
cytes, phagocytes and myeloid cells. Thus, compared to 
other exosomal proteomes, the nasal exosome proteome 
is particularly associated with the immune-regulatory 
functions.
The important comparative analyses of the nasal exo-
some proteome to other proteomes enable a better 
understanding of the exosomes and their potential func-
tion. These analyses are limited by the datasets depos-
ited into the public repositories and are only possible if 
the proteomic datasets are made public by submission 
to proteomic repositories or to the growing number of 
exosomal proteomic databases. Our study highlights the 
importance of submitting proteome lists to public data-
bases, which have enabled the specific features of nasal 
exosomes to be identified.
Validation of proteins identified by mass spectrometry
Several proteins identified by mass spectrometry were 
validated using Western blot or flow cytometry. Pro-
teins were selected for validation if they were com-
mon to exosomes (CD63, CD9 and TSG101), unique to 
nasal exosomes or immune-related (NOS2 and S100A8) 
or potentially indicative of the cellular origin of nasal 
exosomes (the monocyte/macrophage marker, CD14). 
Western blotting confirmed the presence of TSG101, 
NOS2 and S100A8 in exosomes isolated from pools A 
and B, as well as in exosomes of an independent healthy 
subject. Calnexin, an endoplasmic reticulum protein, was 
not identified using mass spectrometry and its absence 
was validated using Western blot (Fig. 4a).
Flow cytometry confirmed the direct presence of CD63 
and CD9 and the indirect presence of MHC class II with 
the use of anti-MHC class II coated beads. The nasal 
exosomes also had minor positivity for CD14, which sug-
gests that at least a small part of the isolated exosomes 
may originate from monocytes or macrophages (Fig. 4b). 
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Fig. 3 Immune-related functions are specifically associated with nasal exosomal. GO Term Finder was used to determine the most enriched cellular 
components (a) and biological processes (b) in the nasal exosomal proteome of healthy subjects, compared to the genome frequency. The 10 
most enriched terms (based on P value) in each category are displayed. c IPA was used to determine the most associated biological functions with 
the nasal exosomal proteome. The 10 most associated biological functions (based on P value) are displayed. d The proteomes of nine previously 
published exosomal studies were analysed with IPA to determine the specificity of the functions associated with the nasal exosomal proteome. The 
top 10 ranked functions associated with nasal lavage exosomes were compared to the rank attained in the other exosomal proteomes. Numbers 
represent the rank (1–10) for a particular function within each exosomal proteome. The nine exosomal proteomes used for the comparison were 
derived from; saliva [19], trabecular meshwork (TM) cells from the eye [23], parotid saliva [18], tracheobronchial ciliated epithelial cells [24], semen 
[16], urine [20–22], breast milk [15] and plasma [17]
iNOS
132 kDa
TSG101
47 kDa
S100A8
11 kDa
Calnexin
75 kDa
Pool A Pool B Indep. donor Cells NOS activity
C
on
ce
nt
ra
tio
n
(µ
M
)
Control NLF exosomes
0
1
2
3
a b cCD9 CD63CD14
Fig. 4 Validation of mass spectrometry identified proteins using Western blot and flow cytometry. a The presence of iNOS, TSG101 and S100A8 
were validated with Western blot in pool A and pool B of healthy subjects and a fifth subject (“indep. donor”). The absence of calnexin in exosomes 
was also demonstrated. b CD14, CD9 and CD63 were validated by binding the exosomes to anti-MHC class II beads and analysis with flow cytom-
etry. Grey filled curve shows isotype control and black open curve shows CD14, CD9 and CD63 respectively. c The iNOS enzyme was demonstrated to 
be biochemically functional by an activity assay. Nitric oxide synthase coverts l-arginine into nitric oxide, which is further converted to nitrite. The 
assay measures the concentration of nitrite (µM), shown on the y-axis. Control samples (“Ctrl”) show the baseline concentration of nitrite in nasal 
exosomes. Nasal lavage exosomes (“NLF exo”) samples shows a higher concentration of nitrite after the assay
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Together, the flow cytometry and Western blot con-
firmed the presence of several of the proteins identified 
with LC–MS/MS by other techniques.
Enzyme activity within nasal exosomes
The innate immune system includes nitric oxide (NO) 
as part of the first response against a bacterial infection, 
which is synthesised by a family of nitric oxide synthase 
enzymes (NOSs). NOS2 is constitutively expressed in 
the airway epithelium, but can be up-regulated during 
inflammation [30, 31]. NOS2 has not previously been 
identified in exosomes (exosomal proteome database, 
EVpedia [14] July, 2015) and the identification of NOS2 
in nasal exosomes is therefore particularly interesting. As 
seen in Fig. 4a, its presence was confirmed in both pools 
of healthy exosomes by Western blot, but importantly, 
the biochemical activity of NOS2 was confirmed in an 
enzyme activity assay (Fig. 4c), showing that the protein 
is not only intact in nasal exosomes, but also biologically 
active.
Altered expression of mucin‑, serum‑, barrier‑ 
and antimicrobial‑associated proteins in exosomes 
from subjects with airway inflammation
A quantitative analysis was conducted to determine 
the influence of respiratory disease on the nasal exo-
some proteome. Exosomes were therefore isolated 
from three groups of subjects; control, asthma only, and 
asthma  +  CRS (clinical characteristics of the patients 
are shown in Table  1, study II). Two independent pools 
of NLF from control, asthma only and asthma  +  CRS 
groups were constructed for proteomic analysis (Fig.  1, 
study II). Of the total 179 proteins identified in the data-
set, 140 proteins were quantified. Proteins quantified 
in all samples of study II (74 proteins) were analysed to 
examine proteins with consistent expression across both 
pools. Consistent expression changes of several pro-
teins were observed in both pools of asthma only and 
asthma +  CRS subjects compared to controls. Mucin-7 
was increased in both disease groups compared to con-
trols (Table 2a), with mucin-5B also increased in asthma 
only (Table  2c). Hypersecretion of mucin is one of the 
hallmark features of asthma [32], with both mucin-7 
and mucin-5B being associated with asthma [33, 34]. 
Furthermore, haptoglobin and hemoglobin subunit 
beta were also increased in both the asthma only and 
asthma + CRS samples compared to control (Table 2a). 
This increase in serum-associated proteins was fur-
ther supported by the increase of serum albumin in 
asthma  +  CRS compared to control (Table  2b). Vascu-
lar proteins have previously been identified in NLF [35], 
but an increase in these proteins compared to control 
may indicate epithelial damage and plasma exudation. 
The increase could also reflect the chronic inflammation 
associated with both asthma and CRS, as haptoglobin is 
an acute phase protein that is associated with inflamma-
tion [36].
A group of S100 proteins; S100A8, S100A9 and 
S100A12, were consistently decreased in NLF exosomes 
from asthma + CRS compared to control (Table 2b) and 
compared to asthma only (Table 2d). S100 proteins have 
been shown to be involved in antifungal and antibacterial 
activity [37], regulation of leukocyte adhesion and migra-
tion and promotion of cytokine and chemokine produc-
tion [38], as well as the induction of pro-inflammatory 
responses in monocytes [39]. Furthermore, S100A8 and 
S100A9 positive exosomes were recently demonstrated 
to be chemotactic for immune cells [40]. The decreased 
expression of these proteins that we found here is con-
sistent with the previous findings that S100 proteins 
are decreased in nasal epithelial cells and NLF from 
patients with CRS [41]. A decrease in the expression 
of S100 proteins could suggest impaired barrier func-
tion and increased susceptibility to bacterial and fungal 
overgrowth. The decreased expression of cathepsin G in 
the asthma + CRS group compared to asthma only may 
be further evidence for decreased antifungal response 
(Table 2d) as cathepsin G deficiency has previously been 
associated with increased susceptibility to fungal infec-
tions [42].
The asthma only group was found to have several 
exosomal proteins with consistently decreased expres-
sion compared to the control group, including filaggrin, 
hornerin and three immunoglobulin-related proteins 
(Table 2c). Both filaggrin and hornerin have been impli-
cated in the barrier function of the skin, with mutations 
in these genes associated with barrier dysfunction, atopic 
dermatitis and increased asthma severity in children [43–
46]. Asthma is an inflammatory airway disorder, however 
there is increasing evidence that the epithelium has an 
important role in the interaction with allergens [47] and 
disease progression [48]. The importance of hornerin and 
filaggrin in the barrier function of the airways requires 
further evaluation, but similar to skin, the airway epithe-
lium is an important barrier of the host defence system.
Conclusion
This study provides the first description of the pro-
teome of nasal exosomes and suggests a potential role 
in upper airways disease. The application of exclusion 
lists increased both the confidence and number of pro-
teins identified, with 604 proteins identified in the nasal 
exosomes of healthy individuals. Many of the identified 
proteins were associated with immune-related functions, 
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which was specific for nasal exosomes compared to pre-
viously published exosomal proteomes. The current study 
is the first to use isobaric tags to quantify exosomal pro-
teins in human disease and it revealed that several groups 
of proteins are consistently altered in nasal exosomes in 
subjects with asthma + CRS and asthma only compared 
to control. An increased expression in exosomal mucin 
and serum-associated proteins was observed in sub-
jects with airway diseases, which may reflect the inflam-
matory processes. The decreased expression in barrier 
and antimicrobial proteins could possibly contribute to 
increased susceptibility to infections, which has impor-
tant clinical implications in disease progression.
The migration of immune cells to the site of inflam-
mation or infection is an important part of the innate 
immune system, especially in the nose, where a strong 
first line of defence is crucial. Interestingly, immune 
cell trafficking was associated with both the baseline 
healthy exosome dataset and with several of the pro-
teins altered with disease. Most importantly, it was also 
Table 2 Proteins with altered expression in airway disease
Only proteins with greater than 1.3-fold change in both pool A and pool B are presented. A negative value (“−”) means negative fold change of the first disease 
compared to second state, while a positive value (“+”) means positive fold change
Acc GenBank accession number; ACTB actin, cytoplasmic 1; ALB serum albumin; CTSG cathepsin G; FLG filaggrin; HBB hemoglobin subunit B; HP haptoglobin; HRNR 
hornerin; IGHA1 Ig alpha-1 chain C region; IGHG1 Ig gamma-1 chain C region; IGJ Immunoglobulin J chain; LACRT extracellular glycoprotein lacritin; LGALS3BP Galectin-
3-binding protein; LTF lactotransferrin; MUC5B mucin-5B; MUC7 mucin-7; MYH9 myosin-9; PIGR polymeric immunoglobulin receptor
a Proteins altered in both asthma + CRS and asthma only against the control
b Proteins altered in asthma + CRS compared to control
c Proteins altered in asthma only compared to control
d Proteins altered in asthma + CRS compared to asthma only
Acc. Protein Asthma + CRS vs control Asthma only vs control Asthma + CRS vs 
Asthma only
A B A B A B
Aa
 Q8TAX7 MUC7 +4.0 +1.4 +2.9 +1.8
 P68871 HBB +2.2 +1.3 +2.0 +2.7
 P00738 HP +1.8 +1.3 +1.7 +1.8
 P02788 LTF −1.5 −1.3 −1.9 −1.6
 Q9GZZ8 LACRT −1.3 −2.0 −1.5 −2.8
Bb
 P02768 ALB +1.3 +1.4
 P01857 IGHG1 +1.3 +1.6
 P05109 S100A8 −1.5 −1.5
 P06702 S100A9 −1.5 −1.4
 P80511 S100A12 −1.4 −2.3
Cc
 Q9HC84 MUC5B +2.2 +2.4
 P20930 FLG −1.4 −2.9
 P01591 IGJ −1.3 −1.5
 P01876 IGHA1 −1.4 −1.3
 P01833 PIGR −1.3 −1.4
 Q86YZ3 HRNR −1.8 −3.8
Dd
 Q08380 LGALS3BP +1.6 +1.5
 Q86YZ3 HRNR +3.6 +1.3
 P05109 S100A8 −1.3 −2.1
 P06702 S100A9 −1.3 −1.9
 P80511 S100A12 −1.6 −1.8
 P60709 ACTB −1.2 −1.5
 P35579 MYH9 −1.6 −1.6
 P08311 CTSG −2.9 −1.5
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demonstrated that nasal exosomes can induce migra-
tion in several immune cells, such as monocytes, NK 
cells and neutrophils in  vitro. This suggests that nasal 
exosomes can participate in the recruitment of immune 
cells to the nose and furthermore, that the capability 
to do so may be altered during inflammatory airway 
diseases.
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